Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy

Allergy, Asthma & Clinical Immunology

Boris Perelman¹  Areej Adil¹  Peter Vadas¹ 

[1] Division of Allergy and Clinical Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto, 30 Bond St., M5B 1 W8 Toronto, ON, Canada

关键词: Apolipoprotein B (apoB);    Low density lipoprotein (LDL);    PAF-acetylhydrolase (PAF-AH);    Platelet-activating factor (PAF);    Anaphylaxis;   

Others  :  791829
DOI  :  10.1186/1710-1492-10-20

 received in 2014-01-06, accepted in 2014-03-31,  发布年份 2014

【 摘 要 】

Background

Platelet-activating factor (PAF) is a highly potent phospholipid mediator responsible for the life-threatening manifestations of anaphylaxis. PAF acetylhydrolase (PAF-AH) inactivates PAF and protects against severe anaphylaxis whereas deficiency of PAF-AH predisposes to severe or fatal anaphylaxis. Determinants of PAF-AH activity have not been studied in patients with peanut allergy.

Objectives

To determine whether plasma PAF-AH activity in patients with peanut allergy is related to formation of circulating complexes with apolipoprotein B (apoB) the main surface protein on low density lipoprotein particles.

Methods

Plasma PAF-AH activity and apoB concentrations were measured in 63 peanut allergic patients (35 boys, 28 girls, ages 2 – 19 years). ApoB concentration was measured immunoturbidimetrically using goat anti-human apoB. The correlation between PAF-AH activity and apoB concentration was determined.

Results

A positive correlation was found between PAF-AH activity and apoB concentration (r² = 0.59, P < 0.0001).

Conclusion

In peanut allergic patients, PAF-AH activity strongly correlates with apoB concentration, suggesting the presence of circulating PAF-AH- lipoprotein complexes.

【 授权许可】

   
2014 Perelman et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Yost CC, Weyrich AS, Zimmerman GA: The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie 2010, 92(6):692-697.
• [2]Miwa M, Miyake T, Yamanaka T, Sugatani J, Suzuki Y, Sakata S, Araki Y, Matsumoto M: Characterization of serum platelet-activating factor (PAF) acetylhydrolase: correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms. J Clin Invest 1988, 82:1983-1991.
• [3]Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA: Platelet-activating factor: a mediator for clinicians. J Intern Med 1995, 238:5-20.
• [4]Arias K, Baig M, Colangelo M, Chu D, Walker T, Goncharova S, Coyle A, Vadas P, Waserman S, Jordana M: Concurrent blockade of platelet-activating factor and histamine prevents life-threatening peanut induced anaphylactic reactions. J Allergy Clin Immunol 2009, 124:307-314.
• [5]Ishii S, Kuwaki T, Nagase T, Maki K, Tashiro F, Sunaga S, Cao WH, Kume K, Fukuchi Y, Ikuta K, Miyazaki J, Kumada M, Shimizu T: Impaired anaphylactic responses with intact sensitivity to endotoxin in mice lacking a platelet-activating factor receptor. J Exp Med 1998, 187:1779-1788.
• [6]Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, Simons FE, Simons KJ, Cass D, Yeung J: Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008, 358:28-35.
• [7]Vadas P, Perelman B, Liss G: Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J Allergy Clin Immunol 2013, 131:144-149.
• [8]Vadas P, Perelman B: Effect of epinephrine on platelet-activating-factor-stimulated human vascular smooth muscle cells. J Allergy Clin Immunol 2012, 129:1329-1333.
• [9]Yanoshita R, Kudo I, Ikizawa K, Chang HW, Kobayashi S, Ohno M, Nojima S, Inoue K: Hydrolysis of platelet activating factor and its methylated analogs by acetylhydrolases. J Biochem 1988, 103:815-819.
• [10]Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM: Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci 1989, 86:2393-2397.
• [11]Karasawa K, Harada A, Satoh N, Inoue K, Setaka M: Review: plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 2003, 42:93-114.
• [12]Stafforini DM, McIntyre TM, M Carter E, Prescott SM: Human plasma platelet-activating factor acetylhydrolase association with lipoprotein particles and role in the degradation of platelet activating factor. J Biol Chem 1987, 262:4215-4222.
• [13]Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH: Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 2000, 150:413-419.
• [14]Zhang B, Fan P, Shimoji E, Itabe H, Miura S, Uehara Y, Matsunaga A, Saku K: Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis 2006, 186:291-301.
• [15]Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM: Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 1999, 274:7018-7024.
• [16]Fielding PE, Fielding CJ: Dynamics of lipoprotein transport in the human circulatory system. In Biochemistry of Lipids, Lipoproteins and Membranes. 4th edition. Edited by Vance DE, Vance JE. Amsterdam: Elsevier; 2002:527-552.
• [17]Vadas P, Liss G: Anaphylaxis: clinical patterns, mediator release and severity. J Allergy Clin Immunol 2013.
• [18]Brown SG, Stone SF, Fatovich DM, Burrows SA, Holdgate A, Celenza A, Coulson A, Hartnett L, Nagree Y, Cotterell C, Isbister GK: Anaphylaxis: Clinical patterns, mediator release, and severity. J Allergy Clin Immunol 2013, 132(5):1141-1149.
• [19]Gardner AA, Reichert EC, Topham MK, Stafforini DM: Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein. J Biol Chem 2008, 283:17099-17106.
• [20]Triggiani M, Granata F, Giannattasio G, Marone G: Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol 2005, 116:1000-1006.
• [21]Vadas P, Browning J, Edelson J, Pruzanski W: Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat 1993, 8:1-30.
• [22]Guerra R, Zhao B, Mooser V, Stafforini DM, Johnston JM, Cohen JC: Determinants of plasma platelet activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res 1997, 38:2281-2288.
• [23]Eisaf M, Tselepis AD: Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol 2003, 66:2069-2073.